## Supplementary data

Suppl. S1: List of primers used for the completion of genome and screening

| Description | Primer name <br> RVA-VP6_40F | Primer sequence ( $5^{\prime} \rightarrow 3^{\prime}$ ) |  |  |  |  |  |  |
| :---: | :---: | :---: | :---: | :---: | :---: | :---: | :---: | :---: |
| Screening primers for human and bat RVAs |  |  | AGR | GAC | $C \text { AAR }$ | R ATT | T GTY | GG |
|  | RVA-VP6_1083R | GWC | CAA | TTC | Atr | CCT | GGT |  |
| ```Primers for completing segments of RVA/Bat- wt/CMR/BatLy03/2014/G 25P[43]``` | RVA59_VP1_301-322R | TTA | GCT | AAT | TTA | CCC | TCA | ACG G |
|  | RVA59_VP1_328-349F | AAG | CTA | ACG | TCA | GAA | tTA | ttc GC |
|  | RVA59_VP1_737-758R | GCT | ACT | AAG | Att | GAC | ATT | GGT G |
|  | RVA59_VP1_2991-3013F | GTC | AAT | AAA | CTA | TGG | CTG | tta CC |
|  | RVA59_VP1_3048-3072F | AtT | AAT | TCG | TAT | ACC | CTT | CAA AgG $T$ |
|  | RVA59_VP3_76-100F | CAA | TCT | TAT | GCT | GAT | ACT | CAA ACG |
|  | RVA59_VP3_787-809R | TGT | CAA | Att | GTG | AAA | TAC | GTC GC |
|  | RVA59_VP3_1795-1818F | CGT | TAT | CTG | GTT | ACA | tat | tta gag |
|  | RVA59_VP4_2063-2084F | GAA | CAG | ATG | GTA | GAT | TTT | tcG C |
|  | RVA59_VP4_171-195R | TAC | AGT | TGT | TGA | AtC | GTT | AAT TtC C |
|  | RVA59_NSP1_1433-1453F | AAA | TCA | CTC | TTA | TTC | CGG | TGG |
|  | RVA59_NSP5_389-411F | ATC | AAT | TAC | TAC | GGA | TCA | TGC TG |
| ```Primers for completing segments of RVA/Bat- wt/CMR/BatLi10/2014/G 30P[42]``` | RVA46_VP4_118-137_F | TTA | CGC | ACC | AGT | GAA | ttg | GG |
|  | RVA46_VP4_839-860_R | ACC |  | tat | AtC | CTA | AAC | CAC |
|  | RVA46_VP7_172-191_F | TCA | ATG | GAC | GTT | GTG | ttg | GC |
|  | RVA46_VP7_803-823_R | GAT | ttg | TTG | TTG | GAT | CTG | ACG |
| Primers for the amplification of 5'and 3' ends of VP7 and VP4 segments | RVA63_VP7-5'-227_R | TTA CTAGAC TCA TGT CCA TCG |  |  |  |  |  |  |
|  | RVA63_VP7-3'-839_F | AGT ATt ACA AGT TGG AGG TGC |  |  |  |  |  |  |
|  | RVA894_VP7-5'-202_R | TGT | AAC | CGG | TAT | GTT | CAA | TCC |
|  | RVA894_VP7-3'-788_F | GTA | AGA | AAA | TCG | GAC | CTA | GAG |
|  | RVA59_VP7-5'-213_R | TCC | AtT | GAT | CCA | GTA | ATT | GGC |
|  | RVA59_VP7-3'-843_F | TAT | AAC | AGC | AGA | тсС | AAC | GAC |
|  | RVA63_VP4-5'-230_R | ATA | CCC | AAT | TAT | CGA | CTG | CTG |
|  | RVA63_VP4-3'-2143_F | CTT | GTA | ACT | GAT | TCA | CCA | GTC |
|  | RVA59_VP4-5'-214_R | AAA | TTC | TGT | TGG | CTG | ATA | GGG |
|  | RVA59_VP4-3'-2100_F | AGA | TTT | TTC | GCA | TAT | AAA | GTG AGC |
|  | RVA894_VP4-5'-158_R | TAC T | TGT | TGA | GTC | Att | TAC | ttc CC |
|  | RVA894_VP4-3'-2072_F | GAA C | CAG | ATG | GTA | GAT | TTT | TCG C |

Suppl. S2: Nucleotide percentage similarity between primers and corresponding sequences of Cameroonian bat RVA strains. -: 5' or 3'-end amplification failed.

| Name of <br> primer | BatLy03 <br> G25P[43] | BatLi08 <br> G31P[42] | BatLi09 <br> G30P[42] | BatLy17 <br> G30P[xx] | BatLi10 <br> G30P[42] | Reference (PMCID) |  |
| :--- | :--- | :--- | :--- | :--- | :--- | :--- | :--- |
| Outer capsid glycoprotein VP7 forward primers | Beg9 | 96.4 | 57.1 | - | 85.7 | - | 269590 |
| sBeg9 | 100 | 57.1 | - | 90.5 | - | 269590 |  |
| 9Con1-L | 100 | 100 | - | 100 | - | 263808 |  |
| Outer capsid glycoprotein VP7 reverse primer |  |  |  |  |  |  |  |
| EndA | 78.2 | 91.3 | 95.7 | - | - | 10364621 |  |
| VP7-Rdeg | 95.0 | 95.0 | 100 | - | - | 114861 |  |
| End9 | 85.1 | 66.7 | 59.3 | - | - | 269590 |  |
| RVG9 | 89.5 | 63.2 | 63.2 | - | - | 269590 |  |

Suppl. S3: Detail explanations of the comparisons between screening primer pairs and the novel bat VP4 and VP7 genotypes

VP7 forward primers Beg9, sBeg9 and 9Con1-L showed a (near) perfect match with BatLy03G25, whereas strain BatLi08-G31 and BatLy17-G30 (first 6 nt are missing for this strain), showed up to 10 and 4 nucleotide mismatches at the 3'end of the primers, respectively. VP7 forward primer 9con1-L showed a perfect match with all the genotypes (G25, G30 and G31). Considering the VP7 reverse primers EndA, VP7-Rdeg, End9 and RVG9, BatLy03-G25 did not show a perfect match as there were $4,1,4$ and 2 mutations, respectively. The mismatches with EndA, VP7-Rdeg and RVG9 were near the middle or at the 5 'end of the primer, whereas 2 of those of End9 were close to the 3 'end. Comparing the same VP7 reverse primers with strain BatLi08-G31 and BatLi09-G30 also showed mismatches. For EndA and VP7-Rdeg maximum 2 mismatches are located in the middle or near the 5 '-end, whereas for End 9 and RVG, there
were multiple mismatches of which 2 and 7 mismatches, respectively were right at the 3 '-end. For VP4 forward primer VP4-1-17F, BatLy03-P[43], BatLi08-P[42], BatLy17-P[xx] and BatLi09-P[42] showed 2, 2, 1 and 2, mismatches, respectively, with at least a mutation at the first position from the 3 'end for all of them. For con 3 , there were $6,7,6$ and 8 mismatches with BatLy03-P[43], BatLi08-P[42), BatLi09-P[42] and BatLy17-P[xx], respectively. Considering the VP4 reverse primer con2, strains BatLy03-P[43], BatLi08-P[42], BatLi09-P[42], BatLy17$\mathrm{P}[\mathrm{xx}]$ and BatLi10-P[42] showed 3-5 mismatches including one at the second position from the 3'-end.

Suppl. S4: Phylogenetic trees of nucleotide sequences of the RVA VP6 sequence. HRVA: Human RVA VP6 sequence from patients exposed to bats; open triangle: Cameroonian bat RVA strains; Other bat RVA: KE4582, MSLH14 and MYAS33. Bootstrap values (1000 replicates) above $70 \%$ are shown. Scale represent number of nucleotide substations per site.


